If you're looking to add some ASX 200 blue chip shares to your portfolio this month, then the three listed below could be worth considering.
These ASX 200 shares have all been named as buys recently. Here's what you need to know about them:
Cochlear Limited (ASX: COH)
The first ASX 200 blue-chip share that could be a buy this month is Cochlear.
It is a leading hearing solutions company with a portfolio of industry-leading cochlear implant devices under the Nucleus brand. The company also has its powerful Baha bone conduction hearing system.
Goldman Sachs is a fan of Cochlear and believes it is well-positioned for long-term growth. The broker has a buy rating and a $280 price target on its shares.
Goodman Group (ASX: GMG)
Another ASX 200 blue chip share that could be a buy is Goodman Group.
Goodman is one of the world's leading integrated commercial and industrial property companies. It has been growing at a solid rate for many years thanks to its world-class portfolio that gives it exposure to key growth markets such as e-commerce and logistics.
Citi is positive on the company and sees Goodman as a "beacon of growth in a sea of earnings declines." Its analysts are forecasting "a >12% EPS CAGR over FY24-FY26."
Citi has a buy rating on its shares with a $24.50 price target on its shares.
ResMed Inc. (ASX: RMD)
A final ASX 200 blue chip share that could be a buy is ResMed.
It is a sleep treatment-focused medical device company with a portfolio of leading hardware and digital solutions.
ResMed's shares have come under pressure recently due to the emergence of obesity drugs. However, Goldman Sachs isn't concerned and feels this has created a buying opportunity. Its analysts "believe a favourable risk-reward skew exists at the current share price."
Goldman has a buy rating and a $33 price target on the company's shares.
